Display options
Cite
Nascimento DR, Balaniuc SLB, Palhares DB, et al. Rare and intractable fibrodysplasia ossificans progressiva shows different PBMC phenotype possibly modulated by ascorbic acid and propranolol treatment. Intractable Rare Dis Res. 2021;10(3):179-189doi: 10.5582/irdr.2021.01012.
Nascimento, D. R., Balaniuc, S. L. B., Palhares, D. B., Underwood, A., Palhares, M. G., Alves, F., Vieira, F. O., Souza-Fagundes, E. M., Giuliani, L. R., Xavier, P. C. N., Puerto, H. L. D., Santos, R. A. S., Milsted, A., Brum, J. M., Silva, I. S., & Martins, A. S. (2021). Rare and intractable fibrodysplasia ossificans progressiva shows different PBMC phenotype possibly modulated by ascorbic acid and propranolol treatment. Intractable & rare diseases research, 10(3), 179-189. https://doi.org/10.5582/irdr.2021.01012
Nascimento, Deborah Ribeiro, et al. "Rare and intractable fibrodysplasia ossificans progressiva shows different PBMC phenotype possibly modulated by ascorbic acid and propranolol treatment." Intractable & rare diseases research vol. 10,3 (2021): 179-189. doi: https://doi.org/10.5582/irdr.2021.01012
Nascimento DR, Balaniuc SLB, Palhares DB, Underwood A, Palhares MG, Alves F, Vieira FO, Souza-Fagundes EM, Giuliani LR, Xavier PCN, Puerto HLD, Santos RAS, Milsted A, Brum JM, Silva IS, Martins AS. Rare and intractable fibrodysplasia ossificans progressiva shows different PBMC phenotype possibly modulated by ascorbic acid and propranolol treatment. Intractable Rare Dis Res. 2021 Aug;10(3):179-189. doi: 10.5582/irdr.2021.01012. PMID: 34466340; PMCID: PMC8397826.
Copy Download .nbib Format: NLM
Share it on

Intractable Rare Dis Res. 2021 Aug;10(3):179-189. doi: 10.5582/irdr.2021.01012.

Rare and intractable fibrodysplasia ossificans progressiva shows different PBMC phenotype possibly modulated by ascorbic acid and propranolol treatment.

Intractable & rare diseases research

Deborah Ribeiro Nascimento, Suzana Lopes Bomfim Balaniuc, Durval Batista Palhares, Adam Underwood, Marilene Garcia Palhares, Fabiana Alves, Francisco Oliveira Vieira, Elaine Maria Souza-Fagundes, Liane De Rosso Giuliani, Paula Cristhina Niz Xavier, Helen Lima Del Puerto, Robson Augusto Souza Santos, Amy Milsted, Jose Mauro Brum, Iandara Schettert Silva, Almir Sousa Martins

Affiliations

  1. UFMS/ Faculty of Medicine, Campo Grande, MS, Brazil.
  2. Walsh University, Division of Mathematics and Sciences, North Canton, OH, USA.
  3. UFMG/ Department of Physiology and Biophysics, Belo Horizonte, MG, Brazil.
  4. Centro Universitário Metodista Izabela Hendrix- IMIH, Belo Horizonte, MG, Brazil.
  5. Procter & Gamble Health Care & Global Clinical Sciences, Mason, OH, USA.

PMID: 34466340 PMCID: PMC8397826 DOI: 10.5582/irdr.2021.01012

Abstract

Fibrodysplasia Ossificans Progressiva (FOP) is a rare congenital intractable disease associated with a mutation in

2021, International Research and Cooperation Association for Bio & Socio - Sciences Advancement.

Keywords: FOP; FOPCON; gene expression modulation; peripheral blood mononuclear cells

Conflict of interest statement

The authors have no conflicts of interest to disclose.

References

  1. Bone. 2018 Apr;109:232-240 - PubMed
  2. Shock. 2003 Feb;19(2):108-12 - PubMed
  3. Genes Nutr. 2014 May;9(3):390 - PubMed
  4. J Clin Invest. 2017 Sep 1;127(9):3339-3352 - PubMed
  5. Nat Genet. 2006 May;38(5):525-7 - PubMed
  6. PLoS One. 2013;8(3):e60021 - PubMed
  7. J Bone Miner Res. 2008 Mar;23(3):305-13 - PubMed
  8. Cytometry B Clin Cytom. 2018 Jul;94(4):613-622 - PubMed
  9. Methods. 2001 Dec;25(4):402-8 - PubMed
  10. J Biol Chem. 2010 Feb 12;285(7):4319-27 - PubMed
  11. Int J Clin Exp Pathol. 2013 Dec 15;7(1):48-55 - PubMed
  12. Expert Opin Orphan Drugs. 2017;5(4):291-294 - PubMed
  13. J Intern Med. 2009 Jun;265(6):663-79 - PubMed
  14. Exp Cell Res. 1997 Sep 15;235(2):362-9 - PubMed
  15. Biochim Biophys Acta. 2002 Jan 15;1569(1-3):1-9 - PubMed
  16. Tex Heart Inst J. 2007;34(3):268-74 - PubMed
  17. J Invest Dermatol. 2001 Jun;116(6):853-9 - PubMed
  18. Physiol Rev. 2018 Jan 1;98(1):505-553 - PubMed
  19. Cent Eur J Immunol. 2015;40(3):373-9 - PubMed
  20. Am J Pathol. 2007 Feb;170(2):620-32 - PubMed
  21. Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13604-9 - PubMed
  22. Gene. 2019 Jul 30;707:151-171 - PubMed
  23. Crit Rev Eukaryot Gene Expr. 2010;20(4):313-24 - PubMed
  24. Br J Clin Pharmacol. 2019 Jun;85(6):1180-1187 - PubMed
  25. Calcif Tissue Int. 1997 Apr;60(4):394 - PubMed
  26. J Biol Chem. 1996 Jun 7;271(23):13900-7 - PubMed
  27. J Bone Miner Res. 2012 Jun;27(6):1252-62 - PubMed
  28. Nat Med. 2004 Apr;10(4):396-401 - PubMed
  29. J Clin Invest. 2007 Jun;117(6):1616-26 - PubMed
  30. J Recept Signal Transduct Res. 2002 Feb-Nov;22(1-4):79-110 - PubMed
  31. Muscle Nerve. 2019 Apr;59(4):501-508 - PubMed
  32. Calcif Tissue Int. 2014 Jun;94(6):621-31 - PubMed
  33. Microsc Res Tech. 2002 Jul 15;58(2):77-84 - PubMed
  34. J Interferon Cytokine Res. 2005 Jul;25(7):384-94 - PubMed
  35. Sci Rep. 2017 Mar 28;7:45597 - PubMed
  36. Bone. 2016 Mar;84:169-180 - PubMed
  37. Cell Signal. 2020 Dec;76:109813 - PubMed
  38. Development. 2016 Nov 1;143(21):3933-3943 - PubMed
  39. Intractable Rare Dis Res. 2019 Feb;8(1):24-28 - PubMed
  40. Oral Dis. 2016 Sep;22(6):463-93 - PubMed
  41. JCI Insight. 2018 Nov 15;3(22): - PubMed
  42. Curr Genomics. 2010 Mar;11(1):52-7 - PubMed
  43. Dev Cell. 2004 Mar;6(3):423-35 - PubMed
  44. Angiogenesis. 2003;6(4):259-69 - PubMed
  45. J Trace Elem Med Biol. 2017 Jan;39:186-192 - PubMed
  46. Immunol Rev. 2012 Jul;248(1):188-204 - PubMed
  47. Pediatr Endocrinol Rev. 2013 Jun;10 Suppl 2:437-48 - PubMed
  48. Biochim Biophys Acta. 2007 Jan;1772(1):32-9 - PubMed
  49. Front Pharmacol. 2015 Aug 13;6:171 - PubMed
  50. Eur J Clin Pharmacol. 1995;48(3-4):295-7 - PubMed
  51. Dev Biol. 2015 Apr 15;400(2):202-9 - PubMed

Publication Types